Rhythm-control strategy with oral cilostazol for refractory protein-losing enteropathy and sinus node dysfunction...

Despite recent advances in therapeutic approaches, treatment for patients with refractory protein-losing enteropathy (PLE) after undergoing the Fontan procedure remains a challenge for clinicians. In this report, we present a Fontan patient in whom oral cilostazol improved PLE with a restored atrial rhythm. We report on a 13-year-old girl with double-outlet right ventricle, ventricular septal defect, l-transposition of the great arteries, and left ventricle hypoplasia. After the Fontan procedure at 16 months of age, she developed PLE at the age of 2 years. As medical treatments such as diuretics, enalapril, heparin, stent implantation for left pulmonary artery, and oral steroids did not lead to remission, intermittent albumin administration was needed. She had ectopic atrial and junctional rhythms, and cardiac catheterization revealed that the junctional rhythm decreased cardiac output and increased central venous pressure. We therefore started her on cilostazol and succeeded in the maintenance of atrial rhythm, resulting in increased serum albumin, globulin, electrolytes, and nutritional status markers with suppression of bowel inflammation. This patient finally was taken off the steroid and returned to a normal school and home life. Oral cilostazol is a possible therapeutic strategy for refractory PLE, as it improves hemodynamics in Fontan patients with sinus node dysfunction.

We present a Fontan patient in whom oral cilostazol for maintaining atrial rhythm improved protein-losing enteropathy (PLE) without any side effects. The junctional rhythm disappeared after the initiation of cilostazol, which suggested that cilostazol stimulated a dominant pacemaker even if the pacemaker was an ectopic focus in the atrium. Oral cilostazol is a possible therapeutic strategy for refractory PLE. We also propose oral cilostazol as a bridging therapy prior to pacemaker implantation.